Gilead’s oncology firm Kite expands existing partnership with Arcellx
Under the expanded collaboration, Kite has also exercised its option to negotiate a licence for Arcellx’s ARC-SparX programme,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Nov 23
Under the expanded collaboration, Kite has also exercised its option to negotiate a licence for Arcellx’s ARC-SparX programme,…
16 Nov 23
The approval was based on the results from the TRIDENT-1 Phase 1/2 trial in which 79% of people…
15 Nov 23
Autifony will lead the drug discovery and preclinical development activities on the two ion channel targets associated with…
15 Nov 23
The combination failed to improve progression-free survival (PFS) against CRT alone in NSCLC patients and showed an enhanced…
15 Nov 23
The combination of Xarelto and Aspirin consistently lowered major adverse limb events (MALE) and major cardiovascular events (MACE)…
15 Nov 23
The collaboration represents a significant expansion of Absci's de novo AI drug creation portfolio into the field of…
14 Nov 23
The acquisition of Forge Biologics is expected to expand Ajinomoto’s AAV and plasmid gene therapy manufacturing capabilities, while…
14 Nov 23
Bylvay is a once-daily, non-systemic ileal bile acid transport inhibitor, designed to act locally in the small intestine…
14 Nov 23
Under the agreement, Aitia will deploy Charles River's Logica across its portfolio of novel drug targets to optimise…
14 Nov 23
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI…